
Kura Oncology And Kyowa Kirin Announce Combination Data For Ziftomenib In Oral Presentation At The 2025 European ...
(MENAFN- GlobeNewsWire - Nasdaq) – Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – – Updated dataset to be presented in oral presentation at EHA2025 Congress – SAN DIEGO and TOKYO, …